Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors

Adoptive therapy with engineered T cells shows promising results in treating patients with malignant disease, but is challenged by incomplete responses and tumor recurrences. Here, we aimed to direct the tumor microenvironment in favor of a successful immune response by local secretion of interleuki...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Oncoimmunology 2018-01, Vol.7 (1), p.e1378842
Hauptverfasser:	Kunert, A., Chmielewski, M., Wijers, R., Berrevoets, C., Abken, H., Debets, R.
Format:	Artikel
Sprache:	eng
Schlagworte:	cytokines Original Research solid tumors T cells TCR gene therapy tumor microenvironment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!